• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

作者信息

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K

机构信息

Department of Breast and Medical Oncology.

Department of Diagnostic Radiology.

出版信息

Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227.

DOI:10.1093/annonc/mdx227
PMID:28505219
Abstract
摘要

相似文献

1
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.64Cu-DOTA-曲妥珠单抗PET成像用于乳腺癌HER2特异性原发性病变
Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227.
2
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.64Cu-DOTA-曲妥珠单抗 PET 显像用于 HER2 阳性乳腺癌患者。
J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12.
3
Tumor Uptake of Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.转移性乳腺癌患者中 Cu-DOTA-曲妥珠单抗的肿瘤摄取。
J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21.
4
Visualization of HER2-specific breast cancer intratumoral heterogeneity using Cu-DOTA-trastuzumab PET.使用铜-多胺大环配体-曲妥珠单抗PET可视化HER2特异性乳腺癌瘤内异质性。
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3.
5
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.89Zr-曲妥珠单抗 PET/CT 检测人表皮生长因子受体 2 阴性原发性乳腺癌患者中人类表皮生长因子受体 2 阳性转移灶
Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.
6
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.使用89Zr-曲妥珠单抗PET/CT检测HER2阴性原发性乳腺癌患者中的HER2阳性转移灶。
J Nucl Med. 2016 Oct;57(10):1523-1528. doi: 10.2967/jnumed.115.172031. Epub 2016 May 5.
7
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.用于检测乳腺癌中人表皮生长因子受体2过表达的双标记曲妥珠单抗成像剂。
J Nucl Med. 2007 Sep;48(9):1501-10. doi: 10.2967/jnumed.107.042234.
8
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.89Zr-曲妥珠单抗的生物分布与转移性乳腺癌患者 HER2 阳性病灶的 PET 成像。
Clin Pharmacol Ther. 2010 May;87(5):586-92. doi: 10.1038/clpt.2010.12. Epub 2010 Mar 31.
9
Towards integration of Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer.旨在将 Cu-DOTA-trastuzumab PET-CT 和 MRI 与数学模型相结合，预测 HER2 阳性乳腺癌新辅助治疗的反应。
Sci Rep. 2020 Nov 25;10(1):20518. doi: 10.1038/s41598-020-77397-0.
10
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.Her2阳性乳腺癌一线全身治疗后的疗效评估——一项观察性横断面研究
Croat Med J. 2015 Apr;56(2):128-38. doi: 10.3325/cmj.2015.56.128.

引用本文的文献

1
The role of radiotheranostics in personalized treatment for breast cancer.放射治疗诊断学在乳腺癌个性化治疗中的作用。
Med Oncol. 2025 Jul 11;42(8):322. doi: 10.1007/s12032-025-02825-y.
2
Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.用于乳腺癌成像的放射性标记HER2靶向分子探针：当前认知与未来展望
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 3. doi: 10.1007/s00210-024-03691-7.
3
Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.
HER2靶向PET/CT成像在乳腺癌患者中的影响及治疗反应监测
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae188.
4
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌的正电子发射断层显像/计算机断层扫描及单光子发射计算机断层显像/计算机断层扫描成像
J Clin Med. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882.
5
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.癌症靶向治疗中的分子和功能影像学：当前应用及未来方向。
Signal Transduct Target Ther. 2023 Feb 27;8(1):89. doi: 10.1038/s41392-023-01366-y.
6
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.乳腺癌核医学显像剂的临床评估
Cancers (Basel). 2022 Apr 23;14(9):2103. doi: 10.3390/cancers14092103.
7
The Prediction of HER2-Targeted Treatment Response Using Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.使用铜-四氮杂环十二烷四乙酸（DOTA）-曲妥珠单抗PET/CT预测转移性乳腺癌中HER2靶向治疗反应：一例报告
J Breast Cancer. 2022 Feb;25(1):69-73. doi: 10.4048/jbc.2022.25.e5. Epub 2022 Jan 21.
8
The blood-tumour barrier in cancer biology and therapy.肿瘤生物学和治疗中的血-肿瘤屏障。
Nat Rev Clin Oncol. 2021 Nov;18(11):696-714. doi: 10.1038/s41571-021-00529-6. Epub 2021 Jul 12.
9
A preliminary clinical trial to evaluate Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer.一项评估Cu-NOTA-曲妥珠单抗作为乳腺癌患者正电子发射断层显像剂的初步临床试验。
EJNMMI Res. 2021 Jan 21;11(1):8. doi: 10.1186/s13550-021-00746-1.
10
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer.用于乳腺癌的PET/CT和PET/MRI分子成像方法的进展与未来趋势
Front Oncol. 2020 Aug 12;10:1301. doi: 10.3389/fonc.2020.01301. eCollection 2020.